Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-05180999 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| PF-05180999 Immediate-Release | EXPERIMENTAL | - |
| PF-05180999 Modified-Release 1 | EXPERIMENTAL | - |
| PF-05180999 Modified-Release 2 | EXPERIMENTAL | - |
| PF-05180999 Modified-Release 1 With Food | EXPERIMENTAL | - |
| PF-05180999 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-05180999 | DRUG | Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation |
| Placebo | DRUG | Placebo oral solution or capsules |
Inclusion Criteria: * Male or female of non-childbearing potential Exclusion Criteria: * Evidence of clinically-significant medical illness, history of seizures, any condition possibly affecting drug absorption
PF-05180999 is an investigational small molecule being studied for use in schizophrenia and in healthy volunteers. It is in Phase 1 clinical development, with studies evaluating its safety, tolerability, and pharmacokinetics. The drug is not approved and remains in early-stage clinical testing.
PF-05180999 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting Phase 1 clinical trials to evaluate the drug's safety, tolerability, and pharmacokinetics in healthy adults and in people with schizophrenia.
PF-05180999 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 studies have been completed, one in healthy adults and one assessing a modified-release formulation, but the drug remains in early-stage testing.
PF-05180999 has been studied in two completed Phase 1 clinical trials. NCT01429740 evaluated the safety, tolerability, and pharmacokinetics of single doses in healthy adults in the United States, with 29 participants. NCT01530529 assessed the relative bioavailability of a modified-release formulation in 12 healthy volunteers.
PF-05180999 is the primary name for this investigational compound. No alternative names have been reported for this drug in the available clinical trial information. It is identified by its Pfizer code name, PF-05180999, in the studies registered under NCT01429740 and NCT01530529.